236 TWELVE-WEEK COURSE OF PIFN-α-2A/RIBAVIRIN IS AN OPTIMIZED REGIMEN FOR TREATMENT OF HCV GENOTYPE 2 BUT NOT GENOTYPE 3 NON-CIRRHOTIC PATIENTS WITH RVR

✍ Scribed by L.E. Adinolfi; R. Zampino; B. Guerrera; L. Restivo; L. Rinaldi; A. Ciervo; V.R. Scialdone; M. Ferrara; G. Ruggiero

• Book ID: 117378322
• Publisher: Elsevier Science
• Year: 2010
• Tongue: English
• Weight: 64 KB
• Volume: 52
• Category: Article
• ISSN: 0168-8278
• DOI: 10.1016/s0168-8278(10)60238-3